Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype - A Prospective Observational Study
This is a prospective observational multi-country, multi-center study of a large real-world cohort of first line (1L) epithelial ovarian cancer patients, exposed to standard of care (SOC) treatment stratified according to BRCA1/2 and HRD status.
• Patients with newly diagnosed histologically confirmed epithelial ovarian cancer:
‣ FIGO stage I-II with a known BRCA1/2 mutation (germline/gBRCA or somatic/tBRCA)
⁃ FIGO stage III-IV of any histology
• Women aged ≥18 years of age at the time of diagnosis
• Patients intended for platinum-based chemotherapy treatment
• Patients capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol
• Patients consent to provide archival tumor tissue sample